• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

靶向小儿肿瘤学中被劫持的激酶信号通路:机遇与现状

Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.

作者信息

Candido Marina Ferreira, Medeiros Mariana, Veronez Luciana Chain, Bastos David, Oliveira Karla Laissa, Pezuk Julia Alejandra, Valera Elvis Terci, Brassesco María Sol

机构信息

Department of Cell Biology, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.

Regional Blood Center, University of São Paulo, Ribeirão Preto 14049-900, SP, Brazil.

出版信息

Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664.

DOI:10.3390/pharmaceutics15020664
PMID:36839989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9966033/
Abstract

Childhood cancer is considered rare, corresponding to ~3% of all malignant neoplasms in the human population. The World Health Organization (WHO) reports a universal occurrence of more than 15 cases per 100,000 inhabitants around the globe, and despite improvements in diagnosis, treatment and supportive care, one child dies of cancer every 3 min. Consequently, more efficient, selective and affordable therapeutics are still needed in order to improve outcomes and avoid long-term sequelae. Alterations in kinases' functionality is a trademark of cancer and the concept of exploiting them as drug targets has burgeoned in academia and in the pharmaceutical industry of the 21st century. Consequently, an increasing plethora of inhibitors has emerged. In the present study, the expression patterns of a selected group of kinases (including tyrosine receptors, members of the PI3K/AKT/mTOR and MAPK pathways, coordinators of cell cycle progression, and chromosome segregation) and their correlation with clinical outcomes in pediatric solid tumors were accessed through the R2: Genomics Analysis and Visualization Platform and by a thorough search of published literature. To further illustrate the importance of kinase dysregulation in the pathophysiology of pediatric cancer, we analyzed the vulnerability of different cancer cell lines against their inhibition through the Cancer Dependency Map portal, and performed a search for kinase-targeted compounds with approval and clinical applicability through the CanSAR knowledgebase. Finally, we provide a detailed literature review of a considerable set of small molecules that mitigate kinase activity under experimental testing and clinical trials for the treatment of pediatric tumors, while discuss critical challenges that must be overcome before translation into clinical options, including the absence of compounds designed specifically for childhood tumors which often show differential mutational burdens, intrinsic and acquired resistance, lack of selectivity and adverse effects on a growing organism.

摘要

儿童癌症被认为是罕见病,约占人类所有恶性肿瘤的3%。世界卫生组织(WHO)报告称,全球每10万居民中普遍有超过15例病例,尽管在诊断、治疗和支持性护理方面有所改善,但每3分钟仍有一名儿童死于癌症。因此,仍需要更高效、更具选择性且更经济实惠的治疗方法,以改善治疗效果并避免长期后遗症。激酶功能的改变是癌症的一个特征,将其作为药物靶点的概念在21世纪的学术界和制药行业中迅速发展。因此,出现了越来越多的抑制剂。在本研究中,通过R2:基因组学分析和可视化平台以及全面检索已发表的文献,研究了一组选定的激酶(包括酪氨酸受体、PI3K/AKT/mTOR和MAPK途径的成员、细胞周期进程协调因子以及染色体分离相关激酶)的表达模式及其与小儿实体瘤临床结果的相关性。为了进一步说明激酶失调在小儿癌症病理生理学中的重要性,我们通过癌症依赖性图谱门户分析了不同癌细胞系对其抑制的敏感性,并通过CanSAR知识库搜索了已获批且具有临床适用性的激酶靶向化合物。最后,我们对大量在实验测试和临床试验中用于治疗小儿肿瘤的、可减轻激酶活性的小分子进行了详细的文献综述,同时讨论了在转化为临床治疗方案之前必须克服的关键挑战,包括缺乏专门为儿童肿瘤设计的化合物,儿童肿瘤往往表现出不同的突变负担、内在和获得性耐药性、缺乏选择性以及对生长中的生物体产生不良反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/41d8cdc73642/pharmaceutics-15-00664-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/afc51816d71c/pharmaceutics-15-00664-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/fcca886a5a78/pharmaceutics-15-00664-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/cde096a2b3ce/pharmaceutics-15-00664-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/666b18710d3a/pharmaceutics-15-00664-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/a4e569e92434/pharmaceutics-15-00664-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/41d8cdc73642/pharmaceutics-15-00664-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/afc51816d71c/pharmaceutics-15-00664-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/fcca886a5a78/pharmaceutics-15-00664-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/cde096a2b3ce/pharmaceutics-15-00664-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/666b18710d3a/pharmaceutics-15-00664-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/a4e569e92434/pharmaceutics-15-00664-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/50e3/9966033/41d8cdc73642/pharmaceutics-15-00664-g006.jpg

相似文献

1
Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.靶向小儿肿瘤学中被劫持的激酶信号通路:机遇与现状
Pharmaceutics. 2023 Feb 16;15(2):664. doi: 10.3390/pharmaceutics15020664.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.帕米塞蒂布(一种选择性 MEK1/2 抑制剂)联合 PI3K/mTOR 抑制剂或多靶点激酶抑制剂在帕米塞蒂布耐药的人肺癌和结直肠癌细胞中的抗肿瘤活性。
Int J Cancer. 2013 Nov;133(9):2089-101. doi: 10.1002/ijc.28236. Epub 2013 May 29.
5
Kinase signalling pathways in endometriosis: potential targets for non-hormonal therapeutics.内异症中的激酶信号通路:非激素治疗的潜在靶点。
Hum Reprod Update. 2016 Apr;22(3):382-403. doi: 10.1093/humupd/dmv060. Epub 2016 Jan 5.
6
Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.儿科脑肿瘤:分子诊断、靶向和免疫治疗时代,以及对长期神经后遗症的关注。
Curr Probl Cancer. 2021 Aug;45(4):100777. doi: 10.1016/j.currproblcancer.2021.100777. Epub 2021 Jul 16.
7
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.《2018年炎症性肠病在加拿大的影响:患有炎症性肠病的儿童和青少年》
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
8
The effectiveness of web-based programs on the reduction of childhood obesity in school-aged children: A systematic review.基于网络的项目对学龄儿童肥胖症减轻的有效性:一项系统评价。
JBI Libr Syst Rev. 2012;10(42 Suppl):1-14. doi: 10.11124/jbisrir-2012-248.
9
Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway.晚期前列腺癌的靶向治疗:抑制PI3K/Akt/mTOR通路。
Curr Cancer Drug Targets. 2009 Mar;9(2):237-49. doi: 10.2174/156800909787580999.
10
Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis.分子神经肿瘤学与脑肿瘤靶向治疗策略的发展。第2部分:PI3K/Akt/PTEN、mTOR、SHH/PTCH与血管生成。
Expert Rev Anticancer Ther. 2004 Feb;4(1):105-28. doi: 10.1586/14737140.4.1.105.

引用本文的文献

1
Aurora kinases signaling in cancer: from molecular perception to targeted therapies.极光激酶在癌症中的信号传导:从分子认知到靶向治疗
Mol Cancer. 2025 Jun 18;24(1):180. doi: 10.1186/s12943-025-02353-3.
2
Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.解析MYC在肉瘤中的作用及其作为有前景治疗靶点的潜力
Int J Mol Sci. 2025 Feb 25;26(5):1973. doi: 10.3390/ijms26051973.
3
Marine-Derived Bisindoles for Potent Selective Cancer Drug Discovery and Development.用于高效选择性抗癌药物研发的海洋来源双吲哚类化合物

本文引用的文献

1
Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.受体酪氨酸激酶抑制剂治疗复发性和不可切除的骨肉瘤。
Int J Mol Sci. 2022 Nov 9;23(22):13784. doi: 10.3390/ijms232213784.
2
The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro.PI3K 抑制剂 pictilisib 以及多激酶抑制剂 pazopanib 和 sorafenib 对体外髓母细胞瘤的 Rac1 水平和迁移有影响。
J Cell Mol Med. 2022 Dec;26(23):5832-5845. doi: 10.1111/jcmm.17604. Epub 2022 Nov 15.
3
Identification of prognostic genes for early basal-like breast cancer with weighted gene co-expression network analysis.
Molecules. 2024 Feb 21;29(5):933. doi: 10.3390/molecules29050933.
4
Allo-targeting of the kinase domain: Insights from in silico studies and comparison with experiments.激酶结构域的 allo 靶向:计算研究的见解及与实验的比较。
Curr Opin Struct Biol. 2024 Feb;84:102770. doi: 10.1016/j.sbi.2023.102770. Epub 2024 Jan 11.
5
Signaling pathways of oxidative stress response: the potential therapeutic targets in gastric cancer.氧化应激反应信号通路:胃癌治疗的潜在靶点。
Front Immunol. 2023 Apr 18;14:1139589. doi: 10.3389/fimmu.2023.1139589. eCollection 2023.
基于加权基因共表达网络分析鉴定早期基底样乳腺癌的预后基因。
Medicine (Baltimore). 2022 Oct 21;101(42):e30581. doi: 10.1097/MD.0000000000030581.
4
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer.极光激酶在头颈部癌症中的治疗靶点。
Cancer J. 2022;28(5):387-400. doi: 10.1097/PPO.0000000000000614.
5
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.恶性肿瘤中蛋白酪氨酸激酶抑制剂耐药性:分子机制及未来展望。
Signal Transduct Target Ther. 2022 Sep 17;7(1):329. doi: 10.1038/s41392-022-01168-8.
6
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.针对非肺或甲状腺肿瘤的 RET 融合阳性实体瘤患者,塞普替尼的肿瘤不可知疗效和安全性(LIBRETTO-001):一项 1/2 期、开放标签、篮子试验。
Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: 10.1016/S1470-2045(22)00541-1. Epub 2022 Sep 12.
7
Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms' tumor.肾母细胞瘤主要信号通路中癌基因与抑癌基因的差异表达谱分析
Pediatr Surg Int. 2022 Nov;38(11):1601-1617. doi: 10.1007/s00383-022-05202-2. Epub 2022 Sep 15.
8
A Novel Ferroptosis-Related Gene Signature for Prognosis Prediction in Ewing Sarcoma.新型铁死亡相关基因签名用于尤文肉瘤预后预测。
Anal Cell Pathol (Amst). 2022 Aug 22;2022:6711629. doi: 10.1155/2022/6711629. eCollection 2022.
9
The hepatocyte growth factor/mesenchymal epithelial transition factor axis in high-risk pediatric solid tumors and the anti-tumor activity of targeted therapeutic agents.高危儿童实体瘤中的肝细胞生长因子/间充质上皮转化因子轴及靶向治疗药物的抗肿瘤活性。
Front Pediatr. 2022 Aug 10;10:910268. doi: 10.3389/fped.2022.910268. eCollection 2022.
10
Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.ARROW 研究中 1/2 期试验:普拉替尼在 RET 融合阳性实体瘤患者中的泛癌疗效。
Nat Med. 2022 Aug;28(8):1640-1645. doi: 10.1038/s41591-022-01931-y. Epub 2022 Aug 12.